The following is a synopsis of this discussion from the CBI Web site: "The government has shown that enforcement against illegal off-label promotion remains a top priority. Hear from current and former prosecutors on what they look for as they build a case, how they interact with the FDA and what red flags they look for in reviewing a file. Also, learn what criteria are applied when deciding how much to settle a case for and how important company compliance programs are in mitigating risk."
This discussion will take place in Washington, D.C. on October 25, 2007.